Glitazone use associated with reduced risk of Parkinson's disease

BACKGROUND: Whether antidiabetic glitazone drugs protect against Parkinson's disease remains controversial. Although a single clinical trial showed no evidence of disease modulation, retrospective studies suggest that a disease‐preventing effect may be plausible. The objective of this study was...

Descripción completa

Detalles Bibliográficos
Autores principales: Brakedal, Brage, Flønes, Irene, Reiter, Simone F., Torkildsen, Øivind, Dölle, Christian, Assmus, Jörg, Haugarvoll, Kristoffer, Tzoulis, Charalampos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5697685/
https://www.ncbi.nlm.nih.gov/pubmed/28861893
http://dx.doi.org/10.1002/mds.27128

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5697685/
https://www.ncbi.nlm.nih.gov/pubmed/28861893
http://dx.doi.org/10.1002/mds.27128

Ejemplares similares